NASDAQ: FDMT
4d Molecular Therapeutics Inc Stock Ownership - Who owns 4d Molecular Therapeutics?

Insider buying vs selling

Have 4d Molecular Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Scott BizilyChief Legal Officer2024-09-16500$16.33
$8.16kSell
Scott BizilyChief Legal Officer2024-09-16500$6.49
$3.25kBuy

1 of 1

FDMT insiders have bought as... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FDMT insiders and whales buy or sell their stock.

FDMT Shareholders

What type of owners hold 4d Molecular Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bvf Inc9.91%4,629,289$31.20MInstitution
Ra Capital Management LP9.77%4,563,211$30.76MInsider
Ra Capital Management LP9.77%4,563,211$30.76MInstitution
Viking Global Investors LP9.10%4,247,914$28.63MInsider
Goldman Sachs Group Inc8.91%4,159,264$28.03MInstitution
Blackrock Inc8.59%4,010,755$27.03MInstitution
Vanguard Group Inc5.86%2,736,671$18.45MInstitution
Novo Holdings A4.28%2,000,000$13.48MInstitution
Janus Henderson Group PLC3.76%1,754,410$11.82MInstitution
Federated Hermes Inc3.57%1,667,338$11.24MInstitution

1 of 3

FDMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FDMT76.15%23.85%Net Buying
OCGN17.73%10.44%Net Selling
ALT37.20%62.80%Net SellingNet Buying
DSGN45.90%54.10%Net SellingNet Selling
TNXP8.34%91.66%Net BuyingNet Buying

4d Molecular Therapeutics Stock Ownership FAQ

Who owns 4d Molecular Therapeutics?

4d Molecular Therapeutics (NASDAQ: FDMT) is owned by 86.48% institutional shareholders, 27.08% 4d Molecular Therapeutics insiders, and 0.00% retail investors. Ra Capital Management LP is the largest individual 4d Molecular Therapeutics shareholder, owning 4.56M shares representing 9.77% of the company. Ra Capital Management LP's 4d Molecular Therapeutics shares are currently valued at $29.80M.

If you're new to stock investing, here's how to buy 4d Molecular Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.